Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 140

Sort by

Sort Order Select

Journal Articles

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4796.

https://doi.org/10.1182/blood-2024-207274

Published: 2024

Journal Articles

Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure

Tim Versteegen, Philipp Nakov, Nikos Darzentas, Guranda Chitadze, Ingram Iaccarino, Wolfram Klapper, Natalie Schub, Monika Brüggemann, Friedrich Stoelzel, Claudia D Baldus, Christiane Pott, Mouhamad Khouja

Blood (2024) 144 (Supplement 1): 2959.

https://doi.org/10.1182/blood-2024-207721

Published: 2024

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features

Blood (2024) 144 (2): 187–200.

https://doi.org/10.1182/blood.2023023242

Published: 2024

Includes: Supplemental data

Journal Articles

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Blood (2024) 144 (1): 74–83.

https://doi.org/10.1182/blood.2024023938

Published: 2024

Includes: Supplemental data

Journal Articles

Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment

Nicole Seifert, Sarah Reinke, Johanna Grund, Berit Müller-Meinhard, Andreas Engert, Peter Borchmann, Paul J Bröckelmann, Michael Altenbuchinger, Wolfram Klapper

Blood (2023) 142 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2023-186527

Published: 2023

Journal Articles

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2023-189047

Published: 2023

Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Blood (2023) 142 (Supplement 1): 71.

https://doi.org/10.1182/blood-2023-178815

Published: 2023

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Erik Van Dijk, Jurriaan Janssen, Matias Mendeville, G. Tjitske Los-De Vries, Margaretha GM Roemer, Phylicia Stathi, Julia Richter, Yong Soo Kim, Wolfram Klapper, Ulrich Dührsen, Andreas Hüttmann, P. J Lugtenburg, Josée M. Zijlstra, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau, Bauke Ylstra

Blood (2022) 140 (Supplement 1): 9261–9263.

https://doi.org/10.1182/blood-2022-160052

Published: 2022

Journal Articles

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2022) 140 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2022-163018

Published: 2022

Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Blood (2022) 140 (Supplement 1): 2283–2285.

https://doi.org/10.1182/blood-2022-156085

Published: 2022

Journal Articles

SOX11, CD70, and T reg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma

Patricia Balsas, Luis Veloza, Guillem Clot, Marta Sureda-Gómez, Marta-Leonor Rodríguez, Christos Masaoutis, Gerard Frigola, Alba Navarro, Silvia Beà, Ferran Nadeu, Eva Giné, Armando López-Guillermo, Antonio Martínez, Inmaculada Ribera-Cortada, Pablo Engel, Leticia Quintanilla-Martínez, Wolfram Klapper, Elias Campo, Virginia Amador

Blood (2021) 138 (22): 2202–2215.

https://doi.org/10.1182/blood.2020010527

Published: 2021

Includes: Supplemental data

Journal Articles

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Verena Passerini, Vindi Jurinovic, Christopher R Bolen, Andrea Knapp, Alessia Bottos, Julia Richter, Jude Fitzgibbon, Wolfram Klapper, Andrew Davies, Robert Marcus, Michael von Bergwelt, Tina Nielsen, Martin H. Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert

Blood (2021) 138 (Supplement 1): 39.

https://doi.org/10.1182/blood-2021-147751

Published: 2021

Journal Articles

Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study

Marie-Helene Delfau, Elizabeth A. Macintyre, Mary B. Callanan, Christiane Pott, Vincent H.J. Van Der Velden, Christa Homburg, Ramon Garcia-Sanz, Paula Gameiro, Maria Gomes Da Silva, Wolfram Klapper, Lucie Oberic, Pierre Feugier, Violaine Safar, Olivier Casasnovas, Martin H. Dreyling, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 40.

https://doi.org/10.1182/blood-2021-145288

Published: 2021

Journal Articles

The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis

Luca Fischer, Linmiao Jiang, Joerg Bittenbring, Kai Hübel, Christian Schmidt, Johannes Duell, Bernd Metzner, Jürgen Krauter, Bertram Glass, Andreas Hüttmann, Kerstin Schaefer-Eckart, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Martin H. Dreyling, Eva Hoster

Blood (2021) 138 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2021-148074

Published: 2021

NARROW

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Genomic profiling for clinical decision making in lymphoid neoplasms

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

SOX11, CD70, and T reg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study

The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only